Published in Health Business Week, January 12th, 2007
Abilify Injection is the third drug formulation commercially available in the United States utilizing CyDex's Captisol enabling technology. The U.S. Food and Drug Administration (FDA) approved Abilify Injection on September 20, 2006.
CyDex's patented Captisol technology improves water solubility, bioavailability and complexation characteristics of insoluble and/or unstable drugs. In addition to injectable products, the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.